FIGURE 1. Tumour-derived MYC mutants show enhanced oncogenicity in vivo.
From the following article:
Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants
Michael T. Hemann, Anka Bric, Julie Teruya-Feldstein, Andreas Herbst, Jonas A. Nilsson, Carlos Cordon-Cardo, John L. Cleveland, William P. Tansey and Scott W. Lowe
Nature 436, 807-811 (11 August 2005)
doi: 10.1038/nature03845
a, Kaplan−Meier curve showing survival at various times after adoptive transfer. b, In vivo GFP imaging shows disseminated lymphomas in a mouse 60 days after reconstitution with HSCs transduced with P57S, but not wild-type MYC. c, Haematoxylin/eosin staining and immunohistochemical staining for B220 (a B cell lineage marker) of lymph node and liver sections of animals harbouring wild-type MYC and P57S lymphomas, showing an aggressive B cell disease with perivascular infiltration of B220-positive tumour cells into the liver.
